12:08 PM EDT, 07/08/2024 (MT Newswires) -- Defence Therapeutics ( DTCFF ) , a Canadian biopharmaceutical company, on Monday said it secured a No Objection Letter (NOL) from Health Canada for its clinical trial of its AccuTOX cancer therapy

The trial allows a "Phase I trial of Intratumoral Administration of ACCUM-002TM as a Monotherapy and in Combination with Opdualag in Patients with Unresectables, Stage IIIB and IV, Melanoma".

The study's main objectives are to determine the safety and tolerability of intratumoral administration of AccuTOX, as a monotherapy and in combination with Opdualag.

The secondary objectives are to obtain preliminary efficacy data and to determine the maximum tolerated dose and recommended Phase 2 Dose of AccuTOX exploits as an immune booster and anti-cancer molecule.

Price: 0.75, Change: -0.04, Percent Change: -5.06